Sunita Zalani

Conseiller Juridique Général chez Intarcia Therapeutics, Inc.

Health Technology

Consumer Services

Postes actifs de Sunita Zalani

Sociétés	Poste	Début	Fin
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Conseiller Juridique Général	05/08/2014	-

Sociétés	Poste	Début	Fin
AMGEN INC.	Conseiller Juridique Général	01/08/2004	01/05/2012
ELI LILLY AND COMPANY	Corporate Officer/Principal	-	-
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Conseiller Juridique Général	-	-

University of Baroda

Doctorate Degree

Internationale

Etats-Unis	5
Inde	2

Opérationnelle

General Counsel	3
Doctorate Degree	1
Corporate Officer/Principal	1

Sectorielle

Health Technology	5
Consumer Services	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	2
AMGEN INC.	Health Technology
ELI LILLY AND COMPANY	Health Technology

Entreprise privées	2
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology
Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.	Health Technology

Entreprise privées

Health Technology